Form 4: Amgen Director Omar Ishrak Reports Acquisition of Common Stock

Director Omar Ishrak reports the acquisition of Amgen common stock through vested Restricted Stock Units (RSUs) under the company's incentive program.

Summary

• On August 9, 2024, Omar Ishrak, a director of Amgen Inc., acquired 108.5305 shares of common stock.
• The acquisition was a result of vested Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program.
• The RSUs vested immediately and are paid in shares of Amgen's common stock on a one-to-one basis.
• The price per share was $0, as the shares were acquired through vesting.
• Following the transaction, Ishrak beneficially owns 4,833.1978 shares of Amgen common stock, which includes 163 Dividend Equivalents (DEs).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction (vesting of RSUs) indicating alignment of director's interests with shareholders, but it's not a major event driving significant positive sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Director share acquisitions are common in the pharmaceutical industry as part of executive compensation packages and alignment of interests with shareholders.

Comparison to Industry Standards

• Director compensation packages often include stock options and RSUs to align their interests with shareholders, similar to practices at companies like Pfizer (PFE) and Johnson & Johnson (JNJ).
• The vesting schedules and terms of these equity grants are typically benchmarked against industry peers to ensure competitiveness and retention.

Stakeholder Impact

• The acquisition of shares by a director can have a slightly positive impact on shareholder confidence.

Key Dates